Johnson & Johnson Stock Primed for Rally? Premarket Insights for Nov 3, 2025
Earnings & Guidance Lift Hopes Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex ($3.67B) and its autoimmune blockbusters driving growth ts2.tech reuters.com. Adjusted EPS of $2.80 beat forecasts, and management raised full-year 2025 product revenue guidance to $93.5–93.9B reuters.com. Such beats and raises were well-received: on Oct. 14 JNJ stock spiked ~2%, closing near $191 ts2.tech. Analysts point out that JNJ now expects 2026 sales growth above 5%, reflecting confidence in its new drug launches and MedTech momentum ts2.tech investing.com. Even as